|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | 急性肾损伤诊断与分类专家共识显示文摘近几十来.临床和基础的研究工作者们针对急性肾功能衰竭(ARF)进行了广泛的研究,尽管我们在该疾病的生理和发病机制方面都取得了长足的进步,但如何将这些知识用于临床,改进ARF患者预后方面的工作却做得十分有限。ARF是由多种病因导致、可发生在各种临床情况之下(儿童或成人、门诊或住院、ICU或非ICU患者)的一种复杂的肾功能紊乱,其临床表现既可以是血肌酐水平的轻微升高,也可以是无尿性肾功能衰竭。 | RL Mehta JA Kellum S Shah B Molitoris C Ronco D Warnock A Levin 王欣 | 2006 | 中华肾脏病杂志2006，22，11： | 348 |
| 2 | 国际疼痛研究协会疼痛定义修订版:概念、挑战和折中显示文摘现行国际疼痛研究协会(IASP)将疼痛定义为'与实际或潜在组织损伤,或描述的类似损伤相关的一种不愉快的感觉和情感体验',该定义是由一个分类小组委员会推荐,并于1979年被IASP理事会所采纳。这一定义已被疼痛领域的卫生保健专业人士和研究人员广泛接受,并被一些行业、政府及非政府组织(包括世界卫生组织)所采用。近年来,一些业内人士认为,随着对疼痛更深入的了解,有必要对这个定义重新审定,并提出了修改建议。因此,2018年,IASP成立了一个主席特别工作小组,该小组是由14名来自多个国家的在疼痛相关的临床和基础科学方面拥有广泛专业知识的人员组成,其任务是评估现行定义及其附带注释,并对其保留还是修改提出建议。本文提供了关键概念的摘要、对IASP会员和公众评论的分析以及两年内委员会对疼痛定义和注释的最终修订意见。特别工作小组最后建议将疼痛定义修改为'与组织损伤或潜在组织损伤相关或类似相关的一种不愉快的感觉和情感体验',并将原来的附带注释更新为一系列简要说明并提供相关词源。今年年初,IASP理事会一致接受了修订后的定义和注释。 | Raja SN.Carr DB Cohen M.Finnerup NB Flor H.Gibson S Keefe FJ.Mogil JS Ringkamp M.Sluka KA Song XJ.Stevens B Sullivan MD.Tutelman PR Ushida T.Vader K 程志祥(译) 许继军(译) 程建国(审校) 刘先国(审校) 刘延青(审校) | 2020 | 中华疼痛学杂志2020，16，5： | 137 |
| 3 | Multiplexed activation of endogenous genes by CRISPR-on, an RNA-guided transcriptional activator system显示文摘允许的技术内长的基因的特定的规定为基因功能的学习是珍贵的并且在治疗学有大潜力。我们创造了在 CRISPR 上系统,由核酸酶死者 Cas9 (dCas9 ) 蛋白质组成的二部件的 transcriptional 使活跃之物与互补顺序与 transcriptional 激活域和单个指南 RNA (sgRNAs ) 熔化了到基因倡导者。我们证明在 CRISPR 上能高效地以一种悦耳的方式在人和老鼠房间激活外长的记者基因。另外,我们证明在 vivo 的柔韧的记者基因激活能被把系统部件注入老鼠接合子完成。而且,我们证明在 CRISPR 上能激活内长的 IL1RN, SOX2,和 OCT4 基因。最有效的基因激活被对近似倡导者有约束力的 3-4 sgRNAs 的簇完成,建议他们在基因正式就职的 synergistic 行动。显著地,当指向多重基因的 sgRNAs 同时被介绍进房间时,柔韧的多路的内长的基因激活被完成。染色体宽的表示介绍表明了系统的高特性。 | Albert W Cheng Haoyi Wang Hui Yang Linyu Shi Yarden Katz Thorold W Theunissen Sudharshan Rangarajan Chikdu S Shivalila Daniel B Dadon Rudolf Jaenisch | 2013 | Cell Research2013，23，10： | 65 |
| 4 | 前庭性偏头痛:诊断标准——Barany学会及国际头痛学会共识文件显示文摘本文提供了前庭性偏头痛的诊断标准,由Barany学会前庭疾患分类委员会及国际头痛学会(IHS)偏头痛分类分委员会共同制定。分类包括前庭性偏头痛及很可能的前庭性偏头痛。与IHS的常规程序相同,前庭性偏头痛作为一种新分类,将首先出现在第3版国际头痛分类(ICHD-3)的附录中。若积累了进一步的证据,很可能的前庭性偏头痛也许会纳入更晚的ICHD版本中。前庭性偏头痛的诊断建立在反复发作的前庭症状、具有偏头痛病史、前庭症状与偏头痛症状间存在时间上的相关性,并排除其他可导致前庭症状的病因。符合前庭性偏头痛诊断的症状包括不同类型的眩晕及头部活动诱发的头晕伴恶心。症状的严重程度必须为中重度。急性发作的持续时间限于5 min^72 h的时间窗内。 | 华驾略 李焰生 Lempert T Olesen J Furman J Waterston J Seemungal B Carey J Bisdorff A Versino M Evers S Newman-Toker D | 2013 | 神经病学与神经康复学杂志2013，10，3： | 60 |
| 5 | 美国国立老化研究所与阿尔茨海默病协会诊断指南写作组:阿尔茨海默病源性轻度认知障碍诊断标准推荐显示文摘美国国立老化研究所(NIA)和阿尔茨海默病协会(ADA)组织了一个工作组,负责阿尔茨海默病(AD)痴呆前症状阶段——即本文所称的AD源性轻度认知障碍(MCI)的诊断标准的制订及完善。该工作组制订了以下两套标准:(1)在缺乏相应条件进行先进影像技术及脑脊液检查时,医务人员适用的核心临床标准;(2)适用于包括临床试验在内的科学研究的研究标准。后者纳入了基于影像技术及脑脊液检查的生物标志物的应用。并根据所出现的生物标志物的性质,将最终MCI诊断的确定性程度分为4个级别。而要使生物标志物有效应用于诊断,并在社区医疗服务中规范使用,尚需做大量的工作。 | McKhann GM Knopman DS Chertkow H Hyman BT Jack CR Jr Kawas CH Klunk WE Koroshetz WJ Manly JJ Mayeux R Mohs RC Morris JC Rossor MN Schehens P Carrillo MC Thies B Weintraub S Phelps CH 贾建平(译) 陆璐(译) 张逸驰(译) 黄丽黄(译) 礼媛(译) | 2012 | 中华神经科杂志2012，45，5： | 51 |
| 6 | 美国国立老化研究所与阿尔茨海默病协会诊断指南写作组:阿尔茨海默病痴呆诊断标准的推荐显示文摘由美国国立老化研究所(NIA)和阿尔茨海默病(AD)协会组织了一个工作组,负责修订1984年版AD痴呆的诊断标准。旨在确保修订后的标准具有足够的灵活性,既可供缺乏神经心理学测验、先进的影像技术和脑脊液检查措施的普通医务人员使用,也可供具备上述措施的科研、临床试验的专业研究者使用。新的标准广泛适用于各种原因的痴呆以及专门针对AD痴呆的标准,保留了1984年版标准中的“很可能的AD痴呆”的总体框架。在过去27年的经验基础上,工作组对临床诊断标准做了一些修改,保留了“可能的AD痴呆”的术语,但对其进行了更有针对性的重新定义。在科研用的“很可能的和可能的AD痴呆”的诊断标准中纳入了生物标志物证据。AD痴呆的核心临床标准仍将是临床实践中诊断的基础,但用生物标志物证据来提高AD痴呆诊断的病理生理学特异性也被人们寄予厚望。要实现AD痴呆的生物标志物诊断,还有许多工作摆在面前。 | McKhann GM Knopman DS Chertkow H Hyman BT Jack CR Jr Kawas CH Klunk WE Koroshetz WJ Manly J J Mayeux R Mohs RC Morris JC Rossor MN Scheltens P Carrillo MC Thies B Weintraub S Phelps CH 贾建平(译) 陆璐(译) 张逸驰(译) 黄丽(译) 韩阅(译) | 2012 | 中华神经科杂志2012，45，5： | 52 |
| 7 | Oxidative stress and male reproductive health显示文摘有缺点的精子功能的主要原因之一是氧化应力,它不仅破坏精子 DNA 的正直而且在精子血浆膜由于蛋白质和类脂化合物的并行的损坏限制这些房间的使肥沃的潜力。如此的氧化压力的起源看起来包含精子线粒体,它有一个趋势作为一篇序言产生 superoxide 阴离子的高水平到进入内在的 apoptotic 串联。不幸地,这些房间有很小的能力因为他们仅仅在基础切除修理(BER ) 拥有第一酶,对如此的攻击作出回应小径, 8-oxoguanine glycosylase 1 (OGG1 ) 。后者成功地创造一个 abasic 地点,而是精子因为他们缺乏下游的蛋白质,不能进一步处理氧化损害(APE1, XRCC1 ) 需要完成修理过程。在第一个有丝分裂的部门的 S 阶段的开始以前继续 BER 小径是卵母细胞的责任。如果一个错误被卵母细胞在开发的这个阶段犯,一个变化将被创造那将在身体在每个房间被代表。如此的机制可以在在作为年龄的后果在他们的细菌线承受了氧化应力的男性的后代观察的童年癌症和另外的疾病解释增加,环境或生活方式因素。在男不孕病人的精子的氧化 DNA 损坏的高流行可以为在 vitro 构思的孩子的健康有含意并且在细菌线为对免费激进的产生的起源的当前的研究担任一位司机。 | Robert J Aitken Tegan B Smith Matthew S Jobling Mark A Baker Geoffry N De Iuliis | 2014 | Asian Journal of Andrology2014，16，1： | 48 |
| 8 | Expression of the B7 - related molecule B7 - H1 by glioma cells: a potential mechanism of immune paralysis显示文摘Human glioblastoma is a highly lethal tumor that is known for its immune inhibitory capabilities.B7-homologue l(B7-H 1),a recently identified homologue of B7.1/2(CD80/86),has been described to exert costimulatoryand immune regulatory functions.We investigated the expression and the functional activity of B7-H 1 in humanglioma cells in vitro and in vivo.Although lacking B7.1/2(CD80/86),all 12 glioma cel1 1ines constitutivelyexpressed B7-H1 mRNA and protein.Exposure to IFN-gamma strongly enhanced B7-H 1 expression.Im- | Wintterle S Schreiner B Mitsdoerffer M Schneider D Chen Meyermann R Weller M Wiendl H | 2003 | 中国神经肿瘤杂志2003，1，4： | 37 |
| 9 | AGNP精神科治疗药物监测共识指南:2011显示文摘治疗药物监测(Therapeutic drug monitoring,TDM),如通过定量测定血清或血浆药物浓度指导用药剂量优化,已经成为对患者进行精神药物治疗的很有价值的工具。在患者用药依从性难以判断、药物耐受性不佳、治疗剂量下无效以及可能存在药代动力学药物-药物相互作用等情况下,测定药物浓度是很有用的。在精神科,有可能明显获益于TDM的主要患者群体包括儿童、孕妇、老年患者、智力障碍患者、涉及司法的患者、已知或怀疑携带药代动力学相关基因变异的患者,以及合并躯体疾病影响药代动力学的患者。然而,只有将TDM充分整合到临床治疗过程中去,才能发挥其优化药物治疗的潜在优势。为了促进TDM的合理应用,神经精神药理学与药物精神病学协会(Arbeitsgemeinschaft für Neuropsychopharmakologie und Pharmakopsychiatrie,AGNP)的TDM专家组在2004年发表了精神药物治疗药物监测指南。之后,随着知识不断更新,又有许多可能需要进行TDM的新药上市。因此,本次更新将神经精神药物的种类扩展到了128种,并将其TDM必要性划分为从'强烈推荐'到'可能有用'的四个等级。经过大量细致且全面的文献检索与分门别类的汇总整理,将基于循证医学理念的'治疗参考浓度范围'和'剂量相关参考浓度范围'呈现给大家。本共识指南引入了'实验室警戒浓度'的新概念,即实验室需要马上告知治疗医生的药物浓度上限。本共识指南还给出了诸如药物作为细胞色素P450酶的底物和抑制剂的性质,代谢物与母药浓度比值的常见范围,以及与结果解释相关的内容,还提供了何时将TDM与遗传药理学检测相结合的建议。遵循本指南,有助于改善许多患者精神药物治疗的效果,特别是那些存在药代动力学异常的患者。TDM是一门交叉学科,有时针对看起来不一致的数据,需要多学科坦诚地讨论,只有这样,患者才能从这种合作中获益。 | Hiemke C Baumann P Bergemann N Conca A Dietmaier O Egberts K Fric M Gerlach M Greiner C Gründer G Haen E Havemann-Reinecke U Jaquenoud Sirot E Kirchherr H Laux G Lutz UC Messer T Müller MJ Pfuhlmann B Rambeck B Riederer P Schoppek B Stingl J Uhr M Ulrich S Waschgler R Zernig G 李文标(译) 果伟(译) 阮灿军(译) 贺静(译) 汤宜朗(审校) 王传跃(审校) | 2016 | 实用药物与临床2016，19，10： | 37 |
| 10 | Impact of postoperative omega-3 fatty acid-supplemented parenteral nutrition on clinical outcomes and immunomodulations in colorectal cancer patients显示文摘AIM: To investigate the effect of omega-3 fatty acid parenteral supplementation postoperatively on clinical outcomes and immunomodulation in colorectal cancer patients. METHODS: Forty-two patients undergoing radical colorectal cancer resection with an indication for total parenteral nutrition postoperatively were enrolled in this prospective, double-blind, randomized, controlled study. Patients received total parenteral nutrition supplemented with either soybean oil (LCT; Intralipid, Fresenius-Kabi, SO group, n = 21) or a combination of omega-3 fish oil and soybean oil (LCT:fish oil = 5:1, fish oil; Omegaven, Fresenius-Kabi, FO group, n = 21), up to a total of 1.2 g lipid/kg per day for 7 d postoperatively. A same volume calorie and nitrogen was administrated. Routine blood test, biochemistry, systemic levels of IL-6 and TNF-α, percentage of CD3+, CD4+, and CD8+ lymphocytes were evaluated preoperatively and on postoperative d 1 and 8. Patient outcome was evaluated considering mortality during the hospital stay, length of postoperative hospital stay, and occurrence of infectious complications. RESULTS: Both lipid regimens were well tolerated. No differences between the two groups were noticed in demographics, baseline blood test, biochemistry, serum levels of IL-6 and TNF-α, percentage of CD4+, CD8+ lymphocytes, and ratios of CD4+/CD8+. Compared with those on postoperative d 1, serum IL-6 levels onpostoperative d 8 were significantly depressed in the FO group than in the reference group (-44.43 ± 30.53 vs -8.39 ± 69.08, P = 0.039). Simultaneously, the ratios of CD4+/CD8+ were significantly increased in the FO group (0.92 ± 0.62 vs 0.25 ± 1.22, P = 0.035). In addition, depression of serum TNF-α levels (-0.82 ± 2.71 vs 0.27 ± 1.67, P = 0.125) and elevation of CD3+ and CD4+ lymphocyte percentage (12.85 ± 11.61 vs 3.84 ± 19.62, P = 0.081, 17.80 ± 10.86 vs 9.66 ± 17.55, P = 0.084, respectively) were higher in the FO group than in the reference group. Patients in the FO group trended to need a shorter postoperative hospital stay (17.45 ± 4.80 d vs 19.62 ± 5.59 d, P = 0.19). No statistically significant difference was found when stratified to mortality and occurrence of infectious complications. CONCLUSION: Postoperative supplementation of omega-3 fatty acids may have a favorable effect on the outcomes in colorectal cancer patients undergoing radical resection by lowering the magnitude of inflammatory responses and modulating the immune response. | Bin Liang, Shan Wang, Ying-Jiang Ye, Xiao-Dong Yang, You-Li Wang, Jun Qu, Qi-Wei Xie, Mu-Jun Yin, Division of Surgical Oncology and Division of Gastroenterological Surgery, Peking University People’s Hospital, Beijing 100044, China Author contributions: Liang B and Wang S contributed equally to this work Liang B and Wang S designed the research Liang B, Ye YJ, Yang XD, Wang YL, Qu J, Xie QW, Yin MJ performed the research and collected the data Wang S and Ye YJ supervised the research Liang B and Ye YJ analyzed the data Liang B wrote the paper and revised the manuscript. | 2008 | World Journal of Gastroenterology2008，14，15： | 31 |
| 11 | Measurement of circulating levels of VEGF-A,-C,and -D and their receptors,VEGFR-1 and -2 in gastric adenocarcinoma显示文摘AIM: To analyze the serum levels and prognostic significance of vascular endothelial growth factor (VEGF) -A,-C,and -D,and their receptors,VEGFR-1 and -2 in gastric adenocarcinomas. METHODS: The serum levels of VEGF family members were measured in 76 control subjects and 76 patients with gastric adenocarcinoma using an enzyme-linked immunosorbent assay (ELISA). These measurements were correlated with clinco-pathological features and survival rates. RESULTS: The serum levels of VEGF-A and its receptor,VEGFR-1,were signifi cantly higher in patients with gastric cancer than in healthy donors (t = 2.3,P = 0.02 and t = 4.2,P < 0.0001,respectively). In contrast,the serum levels of VEGF-D were signif icantly higher in control subjects than in patients (t = 2.9,P = 0.004). There was no significant difference in serum levels of VEGF-C and VEGFR-2 between patients and controls. VEGF-C was associated with advanced tumor stage and presence of metastasis. VEGFR-1 was associated with metastasis,advanced overall stage,tumor differentiation and survival. VEGFR-2 levels were associated with poor tumor differentiation. There was no significant prognostic value for any of the VEGF family members or their receptors except for VEGFR-1 where high levels were associated with a poor overall survival. CONCLUSION: Serum VEGF levels vary significantly in the same cohort of patients with variable clinico-pathological features and prognostic values. The simultaneous measurement of VEGF receptors levels in sera may overcome the limitations of a single biomarker assay. | Mansour S Al-Moundhri A Al-Shukaili M Al-Nabhani B Al-Bahrani IA Burney A Rizivi SS Ganguly | 2008 | World Journal of Gastroenterology2008，14，24： | 32 |
| 12 | 帕博利珠单抗治疗伴脑转移NSCLC患者的一项非随机、开放Ⅱ期试验的长期随访结果和生物标志物分析显示文摘背景与目的我们开展了一项帕博利珠单抗用于伴未治疗脑转移的非小细胞肺癌(non-small cell lung cancer,NSCLC)或黑色素瘤患者的疗效和安全性的II期试验,旨在评估程序性死亡受体1(programmed cell death 1,PD-1)抑制剂在中枢神经系统(central nervous system,CNS)中的疗效。中期结果已发表,现报道对NSCLC队列的更新分析结果。方法这是一项开放性、单中心、II期试验。纳入标准:年龄≥18岁,诊断为晚期NSCLC并伴有≥1个5 mm-20 mm脑转移病灶,既往从未治疗或之前放疗后进展,无神经系统症状,不需要激素治疗且美国东部肿瘤协作组(Eastern Cooperative Oncology Group,ECOG)<2分。患者每2周接受一次帕博利珠单抗(10 mg/kg)治疗。队列1为程序性死亡配体1(programmed cell death ligand 1,PD-L1)≥1%的患者,队列2为PD-L1<1%或未评估的患者。主要终点是脑转移患者缓解比例。所有经治患者均纳入疗效与安全性终点的分析。该研究已结束入组,并于Clinicaltrials.gov登记注册,注册号为NCT02085070。结果2014年3月31日-2018年5月21日,共42例患者接受治疗。中位随访时间为8.3个月(IQR:4.5个月-26.2个月)。队列1的37例患者中11例有脑转移缓解[29.7%(95%CI:15.9%-47.0%)]。队列2未观察到缓解。治疗相关的3级-4级不良事件(adverse events,AEs)包括2例肺炎、1例全身症状、1例结肠炎、1例肾上腺皮质功能不全、1例高血糖症和1例低钾血症。6例(14%)患者发生了治疗相关的严重不良事件,包括肺炎、急性肾损伤、低钾血症和肾上腺皮质功能不全。没有观察到治疗相关死亡病例。结论帕博利珠单抗治疗PD-L1≥1%的NSCLC伴脑转移患者有效,且对所有纳入的未经治疗的脑转移患者安全。需要进一步探索免疫治疗用于NSCLC合并CNS转移。 | Sarah B GOLDBERG Kurt A SCHALPER Scott N GETTINGER Amit MAHAJAN Roy S HERBST Anne C CHANG Rogerio LILENBAUM Frederick H WILSON Sacit Bulent OMAY James B YU Lucia JILAVEANU Thuy TRAN Kira PAVLIK Elin ROWEN Heather GERRSH Annette KOMLO Richa GUPTA Hailey WYATT Matthew RIBEIRO Yuval KLUGER Geyu ZHOU Wei WEI Veronica L CHANG Harriet M KLUGER 董晓荣(翻译/校对) | 2021 | 中国肺癌杂志2021，24，9： | 34 |
| 13 | 最新AD研究用诊断标准:IWG-2标准显示文摘在过去的8年中,国际工作组织(IWG)和美国国立老化研究院-阿尔茨海默协会(NIA-AA)建立了阿尔茨海默病(AD)诊断标准,它能更好地定义AD的临床表型,整合了生物标记物于诊断流程中,并覆盖了疾病的全程。本意见书充分地权衡了IWG标准的优缺点,建议改进诊断框架。依据这些改进,AD的诊断变得简单,只要有恰当的AD临床表型(典型或不典型)和与AD的病理相一致的病理生理学生物标志物出现。我们认为疾病的下游的定位性生物标志,如容积性磁共振成像(MRI)和氟脱氧葡萄糖-正电子发射型计算机断层成像(FDG-PET)等,适合更好地测量和监测疾病过程。本文还详述了非典型性AD、混合性AD和AD临床前期的特异诊断标准。 | 陈刚 曹雯炜 俞羚 糜建华 Dubois B Feldman HH Jacova C Hampel H Molinuevo JL Blennow K DeK osky ST Gauthier S Selkoe D Bateman R Cappa S Crutch S Engelborghs S Frisoni GB Fox NC Galasko D Habert MO Jicha GA Nordberg A Pasquier F Rabinovici G Robert P Rowe C Salloway S Sarazin M Epelbaum S de Souza LC Vellas B Visser PJ Schneider L Stern Y Scheltens P Cummings JL | 2014 | 神经病学与神经康复学杂志2014，11，3： | 31 |
| 14 | Protocatechuic acid from Alpinia oxyphylla against MPP+-induced neurotoxicity in PC12 cells显示文摘 | An LJ Guan S Shi GF Bao YM Duan YL Jiang B | 2006 | 中国生物学文摘2006，20，10： | 30 |
| 15 | 青藏东北缘早第三纪盆地充填的沉积型式及构造背景——以囊谦和下拉秀盆地为例显示文摘一系列中小型早第三纪红色盆地出露于青藏高原的东北缘 ,它们是在印度—欧亚板块碰撞过程中因陆壳变形和高原隆升产生的。典型早第三纪盆地的地质填图和详细的沉积学研究 ,及构造、沉积和岩浆热事件的综合分析表明 ,这些盆地具有两阶段构造—沉积特征 ,即早期受控于逆冲挤压背景 ,盆地接受底部冲积扇体系的粗碎屑岩段沉积 ,局部伴有岩浆活动 ;晚期受控于走滑—拉分背景 ,盆地充填湖泊—三角洲体系的含膏砂泥岩段夹薄层灰岩 ,并伴有广泛的岩浆作用。青藏东北缘早第三纪盆地在盆地构造格架、沉积层序结构、沉积物组成和岩浆活动等方面均存在明显的阶段性演化。盆地古水流统计和岩浆岩4 0 Ar/ 3 9Ar定年结果表明 ,青藏东北缘早第三纪盆地沉积物主要形成于始新世晚期—渐新世早期 (38~ 2 9Ma)。盆地沉积型式和岩浆活动受印度—欧亚板块碰撞早期逆冲挤压和走滑—拉分构造格局的控制。 | 周江羽 王江海 尹安 Spurlin M S Horton B K | 2002 | 沉积学报2002，20，1： | 30 |
| 16 | Structure and function of aggrecan显示文摘Aggrecan is the major proteoglycan in the articular cartilage. This molecule is important in the proper functioning of articular cartilage because it provides a hydrated gel structure (via its interaction with hyaluronan and link protein) that endows the cartilage with load-bearing properties. It is also crucial in chondroskeletal morphogenesis during development. Aggrecan is a multimodular molecule expressed by chondrocytes. Its core protein is composed of three globular domains (G1, G2, and G3) and a large extended region (CS) between G2 and G3 for glycosaminoglycan chain attachment. G1 comprises the amino terminus of the core protein. This domain has the same structural motif as link protein. Functionally, the G1 domain interacts with hyaluronan acid and link protein, forming stable ternary complexes in the extracellular matrix. G2 is homologous to the tandem repeats of G1 and of link protein and is involved in product processing. G3 makes up the carboxyl terminus of the core protein. It enhances glycosaminoglycan modification and product secretion. Aggrecan plays an important role in mediating chondrocyte-chondrocyte and chondrocyte-matrix interactions through its ability to bind hyaluronan. | CHRIS KIANI, LIWEN CHEN, YAO JIONG WU, ALBERT J YEE, BURTON B YANG, Sunnybrook and Women’s College Health Sciences Centre and Department of Laboratory Medicine and Patobiology, 2 Department of Surgeny, Faculty of Medicine, University of Toronto, Canada | 2002 | Cell Research2002，12，1： | 27 |
| 17 | Human mesenchymal stem cells overexpressing pigment epitheliumderived factor inhibit hepatocellular carcinoma in nude mice(摘要)显示文摘 | Gao, Y Yao, A Zhang, W Lu, S Yu, Y Deng, L Yin, A Xia, Y Sun, B Wang, X | 2010 | 南京医科大学学报(自然科学版)2010，30，8： | 25 |
| 18 | Cirrhotic portal hypertension: From pathophysiology to novel therapeutics显示文摘Portal hypertension and bleeding from gastroesophageal varices is the major cause of morbidity and mortality in patients with cirrhosis. Portal hypertension is initiated by increased intrahepatic vascular resistance and a hyperdynamic circulatory state. The latter is characterized by a high cardiac output, increased total blood volume and splanchnic vasodilatation, resulting in increased mesenteric blood flow. Pharmacological manipulation of cirrhotic portal hypertension targets both the splanchnic and hepatic vascular beds. Drugs such as angiotensin converting enzyme inhibitors and angiotensin Ⅱ type receptor 1 blockers, which target the components of the classical renin angiotensin system(RAS), are expected to reduce intrahepatic vascular tone by reducing extracellular matrix deposition and vasoactivity of contractile cells and thereby improve portal hypertension. However, these drugs have been shown to produce significant offtarget effects such as systemic hypotension and renal failure. Therefore, the current pharmacological mainstay in clinical practice to prevent variceal bleeding and improving patient survival by reducing portal pressure is non-selective-blockers(NSBBs). These NSBBs work by reducing cardiac output and splanchnic vasodilatation but most patients do not achieve an optimal therapeutic response and a significant proportion of patients are unable to tolerate these drugs.Although statins, used alone or in combination with NSBBs, have been shown to improve portal pressure and overall mortality in cirrhotic patients, further randomized clinical trials are warranted involving larger patient populations with clear clinical end points. On the other hand, recent findings from studies that have investigated the potential use of the blockers of the components of the alternate RAS provided compelling evidence that could lead to the development of drugs targeting the splanchnic vascular bed to inhibit splanchnic vasodilatation in portal hypertension. This review outlines the mechanisms related to the pathogenesis of portal hypertension and attempts to provide an update on currently available therapeutic approaches in the management of portal hypertension with special emphasis on how the alternate RAS could be manipulated in our search for development of safe, specific and effective novel therapies to treat portal hypertension in cirrhosis. | Lakmie S Gunarathne Harinda Rajapaksha Nicholas Shackel Peter W Angus Chandana B Herath | 2020 | World Journal of Gastroenterology2020，26，40： | 24 |
| 19 | Metabolic profiling analysis of a D-galactosamine/lipopolysaccharide- induced mouse model of fulminant hepatic failure显示文摘 | Feng, B Wu, SM Lv, S Liu, F Chen, HS Yan, XZ Li, Y Dong, FT Wei, L | 2007 | 中国生物学文摘2007，21，11： | 23 |
| 20 | Outcome of patients with acute, necrotizing pancreatitis requiring drainage-does drainage size matter?显示文摘AIM:To assess the outcome of patients with acute necrotizing pancreatitis treated by percutaneous drainage with special focus on the influence of drainage size and number. METHODS:We performed a retrospective analysis of 80 patients with acute pancreatitis requiring percutaneous drainage therapy for infected necroses. Endpoints were mortality and length of hospital stay. The influence of drainage characteristics such as the median drainage size, the largest drainage size per patient and the total drainage plane per patient on patient outcome was evaluated. RESULTS:Total hospital survival was 66%. Thirty-four patients out of all 80 patients (43%) survived acute necrotizing pancreatitis with percutaneous drainage therapy only. Eighteen patients out of all 80 patients needed additional percutaneous necrosectomy (23%). Ten out of these patients required surgical necrosectomy in addition, 6 patients received open necrosectomy without prior percutaneous necrosectomy. Elective surgery was performed in 3 patients receiving cholecystectomy and one patient receiving resection of the parathyroid gland. The number of drainages ranged from one to fourteen per patient. The drainage diameter ranged from 8 French catheters to 24 French catheters. The median drainage size as well as the largest drainage size used per patient and the total drainage area used per patient did not show statistically significant influence on mortality. CONCLUSION:Percutaneous drainage therapy is an effective tool for treatment of necrotizing pancreatitis.Large bore drainages did not prove to be more effective in controlling the septic focus. | T Bruennler J Langgartner S Lang CE Wrede F Klebl S Zierhut S Siebig F Mandraka F Rockmann B Salzberger S Feuerbach J Schoelmerich OW Hamer | 2008 | World Journal of Gastroenterology2008，14，5： | 23 |
您所在的机构暂未开通此部分的功能，请联系管理员